Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1171

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1171
---

to recruit talent from outside of its region, and doing so may be costly and difficult. If Renovaro Cube is unable to attract and retain
highly qualified personnel, its ability to develop and commercialize its products may be limited.

If
Renovaro Cube or BioSymetrics is unable to scale its operations successfully to support demand for its products following the launch of
its platform, its business could suffer.

As and
to the extent demand increases beyond Renovaro Cube’s or BioSymetrics’ expectations following the launch of each’s platform,
Renovaro Cube and BioSymetrics will likely need to start to ramp up operating capacity. We will need to implement new infrastructure,
data processing capabilities, customer service, billing and systems processes, and expand internal quality assurance program and technology
to support operations on a larger scale. We will also need collaboration arrangements with third-party laboratories to process its physical
tests or, if processing of such tests is not fully outsourced to support demand, will need to obtain equipment and certified and licensed
laboratory personnel to process these physical tests internally. We may face difficulties increasing the scale of operations, including
implementing changes in infrastructure or programs or acquiring additional equipment or personnel. As we refine our products and develop
additional products, Renovaro Cube and BioSymetrics may need to introduce new equipment, implement new systems, technology, controls
and procedures, and hire personnel with different qualifications, licenses or certifications.

The value
of Renovaro Cube’s and BioSymetrics’ products will depend, in part, on our ability to perform tests, whether through a licensed
provider or internally, and return results to providers on a timely basis and at an appropriate quality standard, and on our reputation
for such timeliness and quality. Failure to establish necessary arrangements with licensed providers, to implement necessary procedures,
to transition to new equipment or processes, or to hire the appropriately qualified personnel could result in higher costs of processing,
longer turnaround times or an inability to meet market demand. There can be no assurance that Renovaro Cube, BioSymetrics, or any such
licensed provider will be able to perform tests on a timely basis at a level consistent with demand, that we will be able to maintain
the quality of our test results as we scale our commercial operations, or that we will be successful in responding to the potential growing
complexity of its operations, including the related data analysis requirements.

43

In addition,
Renovaro Cube’s and BioSymetrics’ growth